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Purpose: This study was undertaken to investigate the effects of gamma linolenic 
acid (GLA) on inflammation and extracellular matrix (ECM) synthesis in mesan-
gial and tubular epithelial cells under diabetic conditions. Materials and Meth-
ods: Sprague-Dawley rats were intraperitoneally injected with either a diluent 
[n=16, control (C)] or streptozotocin [n=16, diabetes (DM)], and eight rats each 
from the control and diabetic groups were treated with evening primrose oil by ga-
vage for three months. Rat mesangial cells and NRK-52E cells were exposed to 
medium containing 5.6 mM glucose and 30 mM glucose (HG), with or without 
GLA (10 or 100 µM). Intercellular adhesion molecule-1 (ICAM-1), monocyte 
chemoattractant protein-1 (MCP-1), and fibronectin (FN) mRNA and protein ex-
pression levels were evaluated. Results: Twenty-four-hour urinary albumin excre-
tion was significantly increased in DM compared to C rats, and GLA treatment 
significantly reduced albuminuria in DM rats. ICAM-1, MCP-1, FN mRNA and 
protein expression levels were significantly higher in DM than in C kidneys, and 
these increases were significantly abrogated by GLA treatment. In vitro, GLA sig-
nificantly inhibited increases in MCP-1 mRNA expression and protein levels un-
der high glucose conditions in HG-stimulated mesangial and tubular epithelial 
cells (p<0.05, respectively). ICAM-1 and FN expression showed a similar pattern 
to the expression of MCP-1. Conclusion: GLA attenuates not only inflammation 
by inhibiting enhanced MCP-1 and ICAM-1 expression, but also ECM accumula-
tion in diabetic nephropathy.
Key Words:   Gamma linolenic acid, experimental diabetic nephropathy, anti-in-
flammatory, anti-fibrotic
INTRODUCTION
Diabetic nephropathy, the leading cause of end-stage renal disease worldwide, is 
characterized pathologically by cellular hypertrophy and increased extracellular 
matrix (ECM) accumulation.1 The ECM accumulation in diabetic nephropathy 
results in mesangial expansion, tubulointerstitial fibrosis, and irreversible deterio-
ration of renal function.2 Even though previous studies have shown that ECM ac-
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MATERIALS AND METHODS
　　　
Animals
All animal studies were conducted using an approved pro-
tocol the committee for the care and use of laboratory ani-
mals of Yonsei University College of Medicine. Sprague-
Dawley rats weighing 250-280 g were intraperitoneally 
injected with either a diluent [n=16, control (C)] or 65 mg/
kg streptozotocin [n=16, diabetes (DM)]. Diabetes was con-
firmed by tail vein blood glucose levels on the third post-in-
jection day. After confirming diabetes, eight rats each from 
the C and DM groups were treated with 450 mg/kg/day of 
evening primrose oil (EPO, a generous gift from Dalim Bio-
tech, Seoul, Korea) by gavage (C+GLA or DM+ GLA) for 
three months. EPO contained 8-10% GLA, and the amount 
of EPO used in this study provided an approximate GLA 
dose of 40 mg/kg/day. Rats were housed in a temperature-
controlled room and given free access to water and standard 
laboratory chow during the three-month study period.
Body weight and serum glucose level were checked month-
ly, and kidney weight and 24-hour urinary albumin excre-
tion were checked at the time of sacrifice. Blood glucose 
was measured by a glucometer, and 24-hour urinary albu-
min excretion was determined by enzyme-linked immuno-
sorbent assay (ELISA) (Nephrat II, Exocell, Inc., Philadel-
phia, PA, USA).
Cell culture
Primary culture of glomerular mesangial cells was per-
formed as previously described.17 Identification of mesan-
gial cells was performed by their characteristic stellate ap-
pearance in culture and confirmed by immunofluorescent 
microscopy for the presence of actin, myosin, and Thy-1 
antigen, as well as the absence of factor VIII and cytokera-
tin (Synbiotics, San Diego, CA, USA). Mesangial and NRK-
52E cells and immortalized rat tubular epithelial cells, were 
maintained, respectively, in RPMI 1640 and DMEM medi-
um supplemented with 5% fetal bovine serum, 100 U/mL 
penicillin, 100 mg/mL streptomycin, 26 mM NaHCO3, and 
grown at 37ºC in humidified 5% CO2 in air. Subconfluent 
mesangial cells and NRK-52E cells were serum restricted 
for 24 hours, after which the medium was replaced by se-
rum-free medium containing 5.6 mM glucose (NG), 
NG+24.4 mM mannitol (NG+M), or 30 mM glucose (HG) 
with or without 10 or 100 μM GLA (Sigma Chemical Co., 
St. Louis, MO, USA). In addition, both of the cells were 
cumulation under diabetic conditions is attributable to hy-
perglycemia per se, advanced glycation end-products, 
hemodynamic changes, and local growth factors such as 
angiotensin II (AII) and transforming growth factor 
(TGF)-β1,3 the precise molecular and cellular mechanisms 
responsible for this have yet to be resolved.
Recently, accumulating evidence has suggested that the 
inflammatory process also plays an important role in the 
pathogenesis of diabetic nephropathy.4 Infiltration of in-
flammatory cells in glomeruli and renal tubulointerstitium 
is commonly seen in both human diabetic patients and ex-
perimental diabetic animals.5,6 In addition, intracellular 
adhesion molecule-1 (ICAM-1) and monocyte chemoat-
tractant protein-1 (MCP-1), which mediates the recruit-
ment and infiltration of monocytes/macrophages, have 
been shown to be involved in the pathogenesis of diabetic 
nephropathy.7,8 Based on these findings, modulation of the 
inflammatory process is considered to be a potential means 
of preventing the development and progression of diabetic 
nephropathy, and some immunosuppressive agents and 
anti-inflammatory drugs have been found to be beneficial 
in diabetic nephropathy.9,10 Nevertheless, chronic use of 
these drugs in the clinical field is not appropriate due to 
many systemic side effects. Therefore, safe agents for 
chronic treatment of diabetic nephropathy are undoubted-
ly needed.
Polyunsaturated fatty acids (PUFAs), which exist in 
high concentrations in cell membranes as structural phos-
pholipids, are essential to cell integrity and viability.11,12 
There are two classes of PUFAs: ω-3 and ω-6, designated 
according to their carbon ring structure.12 γ-linolenic acid 
(GLA), a member of ω-6 PUFA, is produced from linole-
ic acid by the enzyme δ-6 desaturase, and is elongated to 
dihomogamma linolenic acid (DGLA).11-13 In a previous 
study, GLA was shown to abrogate renal fibrosis in a 5/6 
nephrectomy model,14 and other investigations have dem-
onstrated that GLA treatment improved autoimmune dis-
eases and diabetic neuropathy via an anti-inflammatory 
mechanism.15,16 As mentioned earlier, since the inflamma-
tory process is also involved in the pathogenesis of dia-
betic nephropathy, there is a possibility that GLA may 
ameliorate diabetic nephropathy, but this has never been 
explored.
In this study, therefore, we investigated the effects of GLA 
in experimental diabetic kidneys as well as in high glucose-
stimulated mesangial cells and tubular epithelial cells in re-
gards to inflammation and ECM synthesis.
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GG. CCG-3’; and 18s, sense 5’-AGTCCCTGCCCTTTGT 
ACACA-3’, antisense 5’-GATCCGAGGGCCTCACTA 
AAC-3’. cDNAs from 25 ng RNA of the renal cortical tis-
sue or cultured cells per reaction tube were used for ampli-
fication.
Using the ABI PRISM® 7700 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA), PCR 
was performed with a total volume of 20 μL in each well, 
containing 10 μL of SYBR Green® PCR Master Mix (Ap-
plied Biosystems), 5 μL of cDNA, and 5 pM sense and an-
tisense primers. Primer concentrations were determined by 
preliminary experiments that analyzed the optimal concen-
trations of each primer. Each sample was run in triplicate in 
separate tubes. The PCR conditions were as follows: 35 cy-
cles of denaturation at 94.5ºC for 30 sec, annealing at 60ºC 
for 30 sec, and extension at 72ºC for one minute. Initial 
heating at 95ºC for nine minutes and final extension at 72ºC 
for seven minutes were performed for all PCRs.
After real-time PCR, the temperature was increased from 
60 to 95ºC at a rate of 2ºC/min to construct a melting curve. 
A control without cDNA was run in parallel with each as-
say. The cDNA content of each specimen was determined 
using a comparative CT method with 2-∆∆T. The results are 
given as relative expressions of ICAM-1, MCP-1, and fi-
bronectin normalized to the expression of the 18s house-
keeping gene.
Western blot analysis
The renal cortical tissue and cultured cells harvested from 
plates were lysed in sodium dodecyl sulfate (SDS) sample 
buffer [2% sodium dodecyl sulfate, 10 mM Tris-HCl, pH 
6.8, 10% (vol/vol) glycerol], treated with Laemmli sample 
buffer, heated at 100ºC for five minutes, and electropho-
resed in an 8% acrylamide denaturing SDS-polyacrylamide 
gel. Proteins were then transferred to a Hybond-ECL mem-
brane using a Hoeffer semidry blotting apparatus (Hoeffer 
Instruments, San Francisco, CA, USA). The membrane 
was then incubated in blocking buffer A (1×PBS, 0.1% 
Tween-20, and 8% nonfat milk) at room temperature for 
one hour, followed by an overnight incubation at 4ºC in a 1 
: 1000 dilution of polyclonal antibodies to ICAM-1 (R&D 
systems, Minneapolis, MN, USA), fibronectin (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), or β-actin 
(Sigma Chemical Co., St. Louis, MO, USA). The mem-
brane was then washed once for 15 minutes and twice for 
five minutes in 1×PBS with 0.1% Tween-20. Next, the 
membrane was incubated in buffer A containing a 1 : 1000 
treated by 10 or 100 μM linoleic acid (Sigma Chemical 
Co., St. Louis, MO, USA). At 24 hours after the media 
change, the cells were harvested and conditioned culture 
media were collected.
Total RNA extraction
Total RNA from the renal cortical tissue was extracted as 
previously described.17 Briefly, 100 μL of RNA STAT-60 re-
agent (Tel-Test, Inc., Friendswood, TX, USA) was added to 
the renal cortical tissues, which were lysed by freezing and 
thawing three times. Another 700 μL of RNA STAT-60 re-
agent was then added and the mixture was vortexed and 
stored for five minutes at room temperature. Next, 160 μL 
of chloroform was added and the mixture was shaken vig-
orously for 30 seconds. After three minutes, the mixture 
was centrifuged at 12000×g for 15 minutes at 4ºC and the 
upper aqueous phase containing the extracted RNA was 
transferred to a new tube. RNA was precipitated from the 
aqueous phase by adding 400 μL of isopropanol and then 
pelleted by centrifugation at 12000×g for 30 minutes at 
4ºC. The RNA precipitate was washed with 70% ice-etha-
nol, dried using a Speed Vac, and dissolved in DEPC-treat-
ed distilled water. RNA yield and quality were assessed 
based on spectrophotometric measurements at wavelengths 
of 260 and 280 nm. Total RNA from the mesangial and 
NRK-52E cells was similarly extracted.
Reverse transcription
First strand cDNA was synthesized using a Boehringer 
Mannheim cDNA synthesis kit (Boehringer Mannheim 
GmbH, Mannheim, Germany). Two μg of total RNA ex-
tracted from the renal cortex and cultured cells were reverse 
transcribed using 10 μM random hexanucleotide primer, 1 
mM dNTP, 8 mM MgCl2, 30 mM KCl, 50 mM Tris-HCl, 
pH 8.5, 0.2 mM dithiothreitol, 25 U RNase inhibitor, and 
40 U AMV reverse transcriptase. The mixture was incubat-
ed at 30ºC for 10 minutes and 42ºC for one hour, followed 
by inactivation of the enzyme at 99ºC for five minutes.
Real-time polymerase chain reaction (real-time PCR)
The primers used for ICAM-1, MCP-1, fibronectin, and 18s 
amplification were as follows: ICAM-1, sense 5’-AGGTA 
TCCATCCATCCCAC-3’, antisense 5’-GCCGAGG 
TTCTCGTCTTC-3’; MCP-1, sense 5’-TCTCTTCCTCC 
ACCACTATGCA-3’, antisense 5’-GGCTGAGACAGC 
ACGTGGAT-3’; fibronectin, sense 5’-TGACAACTGCCG 
TAGACCTGG-3’, antisense 5’-TACTGGTTGTAGGTGT 
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respectively, and by a digital image analyzer (MetaMorph 
version 4.6r5, Universal Imaging Corp., Downingtown, PA, 
USA) as previously described.17
The degree of staining was semi-quantitated on a scale of 
0-4+. The staining score was obtained by multiplying the 
intensity of staining by the percentage of glomeruli or tubu-
lointerstitium staining for that intensity, and these numbers 
were then added for each experimental animal to give the 
staining score [Σ=(Intensity of staining)×(% of glomeruli or 
tubulointerstitium with that intensity)]. The number of ED-1 
positive cells was counted in at least 20 glomeruli and 20 
fields of the tubulointerstitium/section under ×400 magnifi-
cation.
Statistical analysis
All values are expressed as the mean±standard error of the 
mean. Statistical analysis was performed using the statistical 
package SPSS for Windows Ver. 11.0 (SPSS, Inc., Chicago, 
IL, USA). Results were analyzed using the Kruskal-Wallis 
non-parametric test for multiple comparisons. Significant dif-
ferences on the Kruskal-Wallis test were further confirmed 
by the Mann-Whitney U test. p-values less than 0.05 were 
considered statistically significant.
 
RESULTS
 
Animal studies
Animal data
All the animals gained weight over the three-month experi-
mental period, but body weight was highest among the C 
rats (593±11 g). The ratio of kidney to body weight in the 
DM rats (1.17±0.15%) was significantly higher than those 
of the C (0.58±0.05%), C+GLA (0.53±0.06%) (p<0.01), 
and DM+GLA (0.88±0.11) (p<0.05) rats. The mean blood 
glucose levels of C, C+GLA, DM, and DM+GLA rats were 
104.1±3.9, 97.6±3.5, 489.5±14.0, and 474.0±13.0 mg/dL, 
dilution of horseradish peroxidase-linked donkey anti-goat 
IgG (Amersham Life Science, Inc., Arlington Heights, IL, 
USA). The washes were repeated, and the membrane was 
developed with a chemiluminescent agent (ECL; Amer-
sham Life Science, Inc., Arlington Heights, IL, USA). The 
band densities were measured using TINA image software 
(Raytest, Straubenhardt, Germany).
Measurement of MCP-1 by ELISA
The levels of MCP-1 in the renal cortical tissue and culture 
media were determined using a commercial ELISA kit (BD 
Biosciences, San Diego, CA, USA) according to the manu-
facturer’s protocol. The kit for rat MCP-1 was species-spe-
cific and sensitive up to 750 pg/mL. All concentrations of 
MCP-1 were normalized to the total protein amount.
Pathology
For immunohistochemical staining, slices of kidney were 
snap-frozen in optimal cutting temperature solution and 4 
μm sections of tissues were utilized. Slides were fixed in 
acetone for 10 minutes, air dried at room temperature for 
10 minutes, and blocked with 10% donkey serum at room 
temperature for 20 minutes. For ICAM-1, fibronectin and 
ED-1 staining, the primary polyclonal antibody to ICAM-1, 
the extracellular domain of fibronectin (Chemicon Interna-
tional, Inc., Billerica, MA, USA) or ED-1 (Chemicon Inter-
national, Inc., Billerica, MA, USA), respectively, was dilut-
ed to 1 : 100 with 2% casein in BSA and was applied for 
overnight incubation at room temperature. After washing, a 
secondary donkey anti-goat antibody was added for 20 
minutes and the slides were then washed and incubated 
with a tertiary PAP complex for 20 minutes. DAB was add-
ed for two minutes and the slides were counterstained with 
hematoxylin. A semi-quantitative score for measuring the 
intensity of ICAM-1 and fibronectin staining within the 
glomeruli and tubulointerstitial area was determined by ex-
amining at least 20 glomeruli under ×400 magnification 
and 20 tubulointerstitial fields under ×200 magnification, 
Table 1. Animal Data for the Four Groups
C (n=8) C+GLA (n=8) DM (n=8) DM+GLA (n=8)
Body Wt (g)  593±11 584±14 328± 9* 335±8*
Kidney Wt/Body Wt (%)    0.58±0.05   0.53±0.06    1.17±0.15*    0.88±0.11†
Blood glucose (mg/dL) 104.1± 3.9  97.6± 3.5  489.5±14.0*   474.0±13.0*
24-hr UAE (mg/day)    0.35±0.07   0.31±0.09    2.51±0.28*    1.11±0.12†
Wt, weight; UAE, urinary albumin excretion; GLA, γ-linolenic acid; C, control; DM, diabetes.
*p<0.01 vs. C and C+GLA group. 
†p<0.05 vs. DM group.
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1 and fibronectin mRNA expression in DM rats (p<0.05) 
(Fig. 1).
Effect of GLA on renal cortical MCP-1 levels and ICAM-1 
and fibronectin protein expression
The levels of renal MCP-1 assessed by ELISA were also 
significantly higher in DM than in C rats (563.5±42.9 vs. 
287.1±22.3 ng/μg, p<0.01), and the increase in MCP-1 lev-
els in DM rats was significantly ameliorated by GLA treat-
ment (354.9±31.3 ng/μg, p<0.05) (Fig. 2). Renal ICAM-1 
and fibronectin protein expression assessed by Western blot 
was also significantly increased in DM rats relative to C 
and C+GLA rats (p<0.01), and GLA treatment significantly 
abrogated these increases in DM rats (p<0.05) (Fig. 3). In 
addition, immunohistochemical staining for ICAM-1 and 
fibronectin confirmed the real-time PCR and Western blot 
findings. There were significant increases in glomerular and 
tubulointerstitial ICAM-1 and fibronectin staining in the 
respectively (p<0.01). Compared to the C group (0.35±0.07 
mg/day), 24-hour urinary albumin excretion at three months 
was significantly higher in DM rats (2.51±0.28 mg/day) 
(p<0.01), and GLA treatment significantly reduced albu-
minuria in DM rats (1.11±0.12 mg/day) (p<0.05) (Table 1).
Effect of GLA on renal cortical MCP-1, ICAM-1, and fibro-
nectin mRNA expression
Renal MCP-1 mRNA expression assessed by real-time PCR 
was significantly higher in DM than in C rats (p<0.01), and 
this increase in MCP-1 mRNA expression was significantly 
inhibited by administration of GLA (p<0.05). The MCP-1 
mRNA/18s rRNA ratio was 2.1-fold higher in DM than in 
C kidneys, and GLA treatment significantly abrogated this 
increase by 65.7%. The ratios of ICAM-1 and fibronectin 
mRNA/18s rRNA were also significantly higher in DM 
compared to C and C+GLA kidneys (p<0.01), and GLA 
treatment significantly attenuated increases in renal ICAM-
Fig. 1. Renal MCP-1, ICAM-1, and fibronectin mRNA/18s rRNA ratios in 
control (C), C+gamma linolenic acid (GLA), diabetic (DM), and DM+GLA 
rats. There was a 2.1-fold increase in MCP-1 mRNA/18s rRNA, a 1.8-fold in-
crease in ICAM-1 mRNA/18s rRNA, and a 2.7-fold increase in fibronectin 
mRNA/18s rRNA ratios in DM rats compared to C rats, and GLA treatment 
significantly abrogated these increases in mRNA/18s rRNA ratios in DM 
rats. *p<0.01 vs. C and C+GLA groups. †p<0.05 vs. DM group. MCP-1, mono-
cyte chemoattractant protein-1; ICAM-1, intracellular adhesion molecule-1.
Fig. 3. Renal ICAM-1 and fibronectin protein expression in C, C+GLA, DM, and DM+GLA rats. There was a 3.2-fold increase in ICAM-1 and a 3.7-fold increase 
in fibronectin protein expression in DM rats compared to C rats, and these increases were significantly attenuated by administration of GLA. *p<0.01 vs. C 
and C+GLA groups. †p<0.05 vs. DM group. ICAM-1, intracellular adhesion molecule-1; C, control; GLA, γ-linolenic acid; DM, diabetes.
Fig. 2. Renal MCP-1 protein levels in C, C+GLA, DM, and DM+GLA rats. 
There was a 2.0-fold increase in renal MCP-1 protein levels in DM rats 
compared to C rats, and this increase in the DM rats was significantly 
ameliorated by GLA treatment. *p<0.01 vs. C and C+GLA groups. †p<0.05 vs. 
DM group. C, control; GLA, γ-linolenic acid; DM, diabetes; MCP-1, mono-
cyte chemoattractant protein-1.
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NRK-52E cells exposed to HG medium (p<0.01), respec-
tively, and GLA treatment significantly ameliorated these 
increases in a dose-dependent manner (p<0.05) (Fig. 5). The 
levels of MCP-1 protein in conditioned culture media as-
sessed by ELISA showed a similar pattern to the mRNA 
expression (Fig. 5). However, linoleic acid did not induce 
significant changes in these patterns (data not shown).
Effect of GLA on ICAM-1 and fibronectin mRNA expression
High glucose significantly induced ICAM-1 and fibronectin 
mRNA expression in mesangial and NRK-52E cells. Com-
pared to NG cells, the ICAM-1 mRNA/18s rRNA ratios 
were 2.2- and 1.8-fold higher in HG-stimulated mesangial 
cells and tubular epithelial cells (p<0.01), respectively, and 
these increases were significantly attenuated by 60.9% and 
62.3%, respectively, with 10 μM GLA treatment, and by 
70.7% and 76.1%, respectively, with 100 μM GLA treat-
ment (Fig. 6). Fibronectin mRNA/18s rRNA ratios were 
significantly increased in HG-stimulated mesangial and 
NRK-52E cells relative to NG cells by 154.4% and 122.2% 
(p<0.01), respectively, and these increases were significant-
DM group compared to the C and C+GLA groups, and these 
increases in DM rats were significantly ameliorated by the 
administration of GLA (Fig. 4). 
Effect of GLA on macrophage accumulation
The number of macrophages within glomeruli and tubu-
lointerstitium assessed by immunohistochemical staining 
with ED-1 antibody was significantly higher in DM rats 
than in C rats (27.8±4.3 vs. 3.6±0.8, p<0.01), and GLA 
treatment significantly abrogated the number of ED-1-posi-
tive cells in DM rats (10.1±1.2) (p<0.05) (Fig. 4).
Cell culture studies
Effect of GLA on MCP-1 mRNA and protein expression
MCP-1 mRNA expression assessed by real-time PCR was 
significantly increased in HG-stimulated mesangial cells and 
NRK-52E cells (p<0.01), and this increase in MCP-1 mRNA 
expression was significantly abrogated by GLA treatment 
(p<0.05). Compared to NG cells, the MCP-1 mRNA/18s 
rRNA ratios were 2.0- and 2.1-fold higher in mesangial and 
Fig. 4. Immunohistochemical staining for glomerular and tubulointerstitial ICAM-1, fibronectin, and ED-1 (as a marker of macrophage) in C, C+GLA, DM, and 
DM+GLA rats. Glomerular (A) and tubulointerstitial (B) ICAM-1 and fibronectin staining was significantly increased in DM rats compared to C rats, and GLA 
treatment significantly inhibited these increases in DM rats. The number of ED-1-positive cells was significantly higher in DM rats than in C rats, and GLA 
treatment significantly abrogated the number of glomerular and tubulointerstitial macrophages in DM rats. (C) IHC scores for ICAM-1 and fibronectin within 
the glomeruli and the tubulointerstitial area were significantly higher in DM rats relative to C rats, and GLA treatment significantly attenuated these increas-
es in DM rats (×400). *p<0.05 vs. other groups. †p<0.01 vs. C and C+GLA groups. ‡p<0.05 vs. DM group. ICAM-1, intracellular adhesion molecule-1; C, control; 
GLA, γ-linolenic acid; DM, diabetes.
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Fig. 6. ICAM-1 and fibronectin mRNA/18s rRNA ratios in mesangial cells (A) and NRK-52E cells (B) exposed to 5.6 mM glucose (NG), NG+24.4 mM mannitol 
(NG+M), NG+10 or 100 μM GLA (NG+GLA), 30 mM glucose (HG), and H+10 or 100 μM GLA (HG+GLA). There were 2.2- and 1.8-fold increases in ICAM-1 
mRNA/18s rRNA ratios in HG-stimulated mesangial cells and NRK-52E cells, respectively, compared to NG cells, and these increases in ICAM-1 mRNA/18s 
rRNA ratios were significantly abrogated by administration of GLA. There were 2.5-fold and 2.2-fold increases in fibronectin mRNA/18s rRNA ratios in HG-
stimulated mesangial cells and NRK-52E cells, respectively, compared to NG cells, and GLA treatment significantly attenuated these increases in fibronectin 
mRNA/18s rRNA ratios in a dose-dependent manner. *p<0.01 vs. NG, NG+M, and NG+GLA groups. †p<0.05 vs. HG group. ICAM-1, intracellular adhesion mol-
ecule-1, GLA, γ-linolenic acid.
Fig. 5. MCP-1 mRNA/18s rRNA ratios and secreted MCP-1 protein levels in mesangial cells (A) and NRK-52E cells (B) exposed to 5.6 mM glucose (NG), 
NG+24.4 mM mannitol (NG+M), NG+10 or 100 μM GLA (NG+GLA), 30 mM glucose (HG), and HG+10 or 100 μM GLA (HG+GLA). There were 2.0- and 2.1-fold in-
creases in MCP-1 mRNA/18s rRNA ratios in the HG-stimulated mesangial and NRK-52E cells, respectively, compared to the NG cells, and these increases in 
MCP-1 mRNA expression were significantly ameliorated by GLA treatment in a dose-dependent manner. There were 2.4- and 3.6-fold increases in MCP-1 
levels in HG-stimulated mesangial cells and NRK-52E cells, respectively, compared to NG cells, and GLA significantly attenuated these increases in MCP-1 
levels in a dose-dependent manner. *p<0.01 vs. NG, NG+M, and NG+GLA groups. †p<0.05 vs. HG group. MCP-1, monocyte chemoattractant protein-1; GLA, 
γ-linolenic acid.
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ed by inhibiting increases in MCP-1 and ICAM-1 expres-
sion under diabetic conditions.
Even though the diabetic milieu per se, hemodynamic 
changes, and local growth factors such as AII and TGF-β 
are considered mediators in the pathogenesis of diabetic ne-
phropathy,3,6 recent studies suggest that an inflammatory 
mechanism may also contribute to the development of dia-
betic nephropathy based on the pathological findings of in-
flammatory cell infiltration in diabetic kidneys.4 Mono-
cytes/macrophages are the major inflammatory cells found 
in diabetic kidneys.5,17 They are extravasculated from the 
bloodstream and attracted to the target tissue through a pro-
cess mediated by various chemokines and adhesion mole-
cules such as MCP-1 and ICAM-1.7,18 In the kidneys, MCP-
1 is expressed in mesangial cells and tubular epithelial cells 
and is known to be involved in the pathogenesis of various 
renal diseases, including diabetic nephropathy.7,19 Previous 
studies have demonstrated that plasma MCP-1 levels are 
ly abrogated by GLA in a dose-dependent manner (p<0.05) 
(Fig. 6). 
Effect of GLA on ICAM-1 and fibronectin protein expression
ICAM-1 and fibronectin protein expression showed similar 
patterns to their mRNA expressions. GLA also significantly 
inhibited HG-induced ICAM-1 and fibronectin protein ex-
pression in cultured mesangial cells and NRK-52E cells 
(Fig. 7).
DISCUSSION
In the present study, we demonstrated that GLA has a reno-
protective effect via its anti-inflammatory and anti-fibrotic 
actions in experimental diabetic nephropathy. In addition, 
the results of this study suggested that the anti-inflammato-
ry effect of GLA under diabetic conditions is partly mediat-
Fig. 7. Representative Western blots of ICAM-1 and fibronectin in cultured mesangial cells (A) and NRK-52E cells (B). There were significant increases in 
ICAM-1 and fibronectin protein expression in HG-stimulated cells as compared to NG cells, and these increases were significantly ameliorated with GLA 
treatment. *p<0.01 vs. NG, NG+M, and NG+GLA groups. †p<0.05 vs. HG group. ICAM-1, intracellular adhesion molecule-1, GLA, γ-linolenic acid.
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FAs are beneficial to one’s overall health and a number of 
various diseases.13 In cases of kidney disease, PUFAs have 
been reported to have beneficial effects on IgA nephropa-
thy,27 chronic renal failure, and diabetic nephropathy via anti-
oxidant, anti-inflammation, and anti-fibrotic mechanisms.13,28 
In contrast, the effect of GLA, a member of the ω-6 PUFA 
family, on kidney diseases has been less explored. Ingram ,et 
al.14 observed that administration of borage oil (BO), a rich 
source of GLA, was effective in a rat 5/6-renal-ablation 
model. BO prevented increases in blood pressure and pro-
teinuria, rising plasma cholesterol levels, and declining glo-
merular filtration rates. In addition, glomerular macrophage 
infiltration, mesangial expansion, and glomerulosclerosis 
were attenuated in BO-treated rats compared to the control 
diet group. Meanwhile, since these glomerular changes are 
also characteristic of diabetic nephropathy, the activities of 
δ-5 and δ-6 desaturase are decreased along with low levels 
of GLA and DGLA in diabetes,29 and since GLA has prov-
en useful in diabetic neuropathy,16,30 supplementation of 
GLA and/or DGLA may also be of benefit in diabetic ne-
phropathy. However, the effect of ω-6 PUFA has never been 
elucidated in diabetic nephropathy. The results of the pres-
ent study showed for the first time that GLA inhibits in-
flammatory cell infiltration and ECM accumulation in ex-
perimental diabetic kidneys, suggesting the usefulness of 
GLA in patients with diabetic nephropathy.
Even though the underlying mechanisms of the anti-in-
flammatory effect of GLA in this study are not completely 
understood, several plausible explanations can be proposed. 
First, PUFAs, including GLA, are known to serve as endog-
enous ligands of peroxisome proliferator activated recep-
tors (PPARs) and to bind and activate all PPARs isoforms.31 
Additionally, 15-HETE, one of the metabolites of GLA, has 
been reported to upregulate nuclear PPAR-γ expression.32 
PPARs participate in regulating inflammatory responses by 
inhibiting monocyte expression of proinflammatory cyto-
kines such as IL-6, IL-1β, and TNF-α.33 Furthermore, 
PPAR-γ attenuates the nuclear factor-κB-mediated transcrip-
tional activation of proinflammatory genes.33 Recent studies 
have also demonstrated that PPAR-γ agonist exerts a reno-
protective effect through an anti-inflammatory mechanism 
in diabetic nephropathy.34 Taken together, GLA, as a ligand 
of PPARs and its metabolite, as well as an upregulator of 
PPAR-γ, could induce an anti-inflammatory effect in dia-
betic nephropathy. Second, a small amount of DGLA can 
be converted to prostacyclin (PGI2) and prostaglandin E1 
(PGE1) by δ-5 desaturases. Because PGI2 and PGE1 inhib-
higher in type 1 diabetes with microalbuminuria20 and that 
urinary levels of MCP-1 are higher in accordance with the 
extent of albuminuria.7 Renal expression of ICAM-1, a cell 
surface glycoprotein that plays a major role in the regula-
tion of interactions with immune cells and whose expres-
sion is upregulated at sites of inflammation,8,21 is also known 
to be increased in experimental type 1 and type 2 diabetic 
animals.17,21 These findings suggest that MCP-1 and ICAM-
1 may play an important role in the pathogenesis of diabetic 
nephropathy by inducing inflammatory cell infiltration.7,8 
Once the recruited monocytes/macrophages are activated, 
they release lysosomal enzymes, nitric oxide, reactive oxy-
gen species, platelet-derived growth factor (PDGF), tumor 
necrosis factor-α, interleukin (IL)-1, and TGF-β, in turn 
promoting renal injury.5,6,22 PDGF stimulates fibroblast pro-
liferation6 and IL-1 induces the expression of TGF-β, the 
most well-known profibrotic cytokine, in fibroblasts.5 In 
experimental diabetic nephropathy, various anti-inflamma-
tory agents inhibited not only inflammatory cell infiltration 
by abrogating increases in MCP-1 and ICAM-1 expression 
but also ameliorated ECM accumulation.17,23 In addition, re-
nal fibrosis was significantly inhibited along with less in-
flammatory cell infiltration in MCP-1- and ICAM-1-defi-
cient diabetic mice.24,25 Taken together, this suggests that the 
inhibition of inflammatory cell recruitment may lead to an 
attenuation of ECM accumulation. In this study, we demon-
strated that MCP-1 and ICAM-1 expression were increased 
in experimental diabetic nephropathy, which were associat-
ed with glomerular and tubulointerstitial fibrosis, and in 
high glucose-stimulated mesangial cells and tubular epithe-
lial cells, and these increases under diabetic conditions were 
inhibited by GLA treatment. In addition, GLA reduced the 
ratio of kidney/body weight in diabetic rats, suggesting GLA 
prevents diabetes-induced kidney enlargement. A recent study 
also demonstrated that prevention of glomerular hypertro-
phy ameliorates the development of diabetic nephropathy, 
including proteinuria and podocytopenia.26 Taken together, 
the anti-inflammatory, anti-fibrotic, and anti-hypertrophic 
effects of GLA in diabetic nephropathy may be partly at-
tributable to the suppression of MCP-1 and ICAM-1 ex-
pression by GLA, by which inflammatory cell infiltration is 
abrogated, in turn ameliorating ECM accumulation.
PUFAs are important constituents of all cell membranes. 
Since PUFAs are not synthesized in humans, they can only 
be obtained by diet.11 There are two classes of PUFAs: ω-3 
and ω-6, designated according to their carbon ring struc-
ture;12 and accumulating evidence has shown that these PU-
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6. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, et 
al. Cellular events in the evolution of experimental diabetic ne-
phropathy. Kidney Int 1995;47:935-44.
7. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai 
K. Possible relationship of monocyte chemoattractant protein-1 
with diabetic nephropathy. Kidney Int 2000;58:684-90.
8. Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kush-
iro M, et al. Increased expression of intercellular adhesion mole-
cule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltra-
tion is a potential mechanism of ICAM-1 upregulation. Diabetes 
1997;46:2075-81.
9. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, 
Zatz R. Mycophenolate mofetil prevents the development of glo-
merular injury in experimental diabetes. Kidney Int 2003;63:209-16.
10. Nasrallah R, Robertson SJ, Hébert RL. Chronic COX inhibition 
reduces diabetes-induced hyperfiltration, proteinuria, and renal 
pathological markers in 36-week B6-Ins2 (Akita) mice. Am J 
Nephrol 2009;30:346-53.
11. Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty 
acids: biochemical, nutritional and epigenetic properties. J Am 
Coll Nutr 2004;23:281-302.
12. Buist PH. Fatty acid desaturases: selecting the dehydrogenation 
channel. Nat Prod Rep 2004;21:249-62.
13. Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid 
in human health and nutrition. J Nutr 1998;128:1411-4.
14. Ingram AJ, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick 
DJ, et al. Dietary alteration of dihomogamma-linolenic acid/ara-
chidonic acid ratio in a rat 5/6-renal-ablation model. The Nutrition 
& Kidney Disease Research Group. J Am Soc Nephrol 1996;7: 
1024-31.
15. Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, 
Temming JE, et al. gamma-Linolenic acid treatment of rheuma-
toid arthritis. A randomized, placebo-controlled trial. Arthritis 
Rheum 1996;39:1808-17.
16. Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, et al. 
Treatment of diabetic neuropathy with gamma-linolenic acid. The 
gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care 
1993;16:8-15.
17. Li JJ, Lee SH, Kim DK, Jin R, Jung DS, Kwak SJ, et al. Colchi-
cine attenuates inflammatory cell infiltration and extracellular ma-
trix accumulation in diabetic nephropathy. Am J Physiol Renal 
Physiol 2009;297:F200-9. 
18. Huang GT, Eckmann L, Savidge TC, Kagnoff MF. Infection of 
human intestinal epithelial cells with invasive bacteria upregulates 
apical intercellular adhesion molecule-1 (ICAM)-1) expression 
and neutrophil adhesion. J Clin Invest 1996;98:572-83.
19. Rovin BH, Yoshiumura T, Tan L. Cytokine-induced production of 
monocyte chemoattractant protein-1 by cultured human mesangial 
cells. J Immunol 1992;148:2148-53.
20. Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M, et 
al. Circulating monocyte chemoattractant protein-1 and early de-
velopment of nephropathy in type 1 diabetes. Diabetes Care 
2002;25:1829-34.
21. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, 
Schmidt H, et al. Early events leading to renal injury in obese Zuck-
er (fatty) rats with type II diabetes. Kidney Int 2000;57:167-82.
22. Yeo ES, Hwang JY, Park JE, Choi YJ, Huh KB, Kim WY. Tumor 
necrosis factor (TNF-alpha) and C-reactive protein (CRP) are pos-
itively associated with the risk of chronic kidney disease in pa-
it platelet aggregation, and PGI2 analogue abrogates glo-
merular hyperfiltration and macrophage infiltration in dia-
betic kidneys,35 the effect of GLA may be in part attributed 
to these consequences. Third, 15-HETE markedly inhibits 
the generation of leukotriene, which is a potent pro-inflam-
matory mediator, via stimulating adhesion molecule ex-
pression and macrophage infiltration.36 Collectively, the an-
ti-inflammatory effect of GLA seems to be attributable to 
the modulation of biological cascades at multiple sites by 
itself and/or its metabolites. Prolonged use of anti-inflam-
matory drugs may be harmful and is not appropriate for 
long-term use due to many systemic side effects in patients 
with chronic metabolic disturbances such as diabetic ne-
phropathy. However, since the activities of both δ-5 and δ-6 
desaturase are already reduced in diabetes and the toxic ef-
fects of GLA as a medicinal oil have not been reported, 
chronic administration of GLA, even at a high dosage, may 
not induce accumulation of its metabolites and thus would 
not be harmful.
In summary, the results of the present study demonstrate 
that GLA exerts anti-inflammatory and anti-fibrotic effects 
in experimental diabetic nephropathy and in high glucose-
stimulated renal cells, suggesting that GLA supplementa-
tion could be a valuable therapeutic option for the treatment 
of diabetic nephropathy.
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